Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardlytics, Inc.CDLX · Entity 7603 | Director | November 08, 2022 | November 10, 2022 |
| Evergy, Inc.EVRG · Entity 3282 | Director | April 01, 2020 | April 02, 2020 |
| Plum Acquisition Corp. IIIAPTMU · Entity 83854 | Director | July 27, 2021 | July 27, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardlytics, Inc.
Report date November 08, 2022 · Filed November 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 248,779 |
Reported balance
After 2022-11-08 transaction · row 1
1 source rowRow 1 · 2022-11-08 · Sale · Disposed 6 · Balance 248,779 F1: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on October 6, 2022. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 55,832 |
Reported balance
Holding disclosure · report date 2022-11-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 55,832 F2: The reportable securities are held by the UTMA Custodial account fbo Pierce Grimes. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 53,112 |
Reported balance
Holding disclosure · report date 2022-11-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 53,112 F3: The reportable securities are held by the 2013 Scott Grimes GRAT UAD. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on October 6, 2022.
F2: The reportable securities are held by the UTMA Custodial account fbo Pierce Grimes.
F3: The reportable securities are held by the 2013 Scott Grimes GRAT UAD.
Evergy, Inc.
Report date April 01, 2020 · Filed April 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 13,666 |
Reported balance
After 2020-04-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-01 · Grant · Acquired 455 · Balance 13,666 F1: Director Deferred Share Units represent the right to receive one share of Evergy, Inc. ("Evergy") common stock, plus, if applicable, stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person. F2: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person. F3: Includes 122 deferred share units acquired through the reinvestment of dividend equivalents. |
| Common StockSEC Table I · non-derivative | Direct | 788 |
Reported balance
Holding disclosure · report date 2020-04-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 788 |
Filing footnotes · ownership attribution and instrument terms
F1: Director Deferred Share Units represent the right to receive one share of Evergy, Inc. ("Evergy") common stock, plus, if applicable, stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.
F2: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person.
F3: Includes 122 deferred share units acquired through the reinvestment of dividend equivalents.
Plum Acquisition Corp. III
Report date July 27, 2021 · Filed July 27, 2021
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GREAT PLAINS ENERGY INC
Report date June 04, 2018 · Filed June 05, 2018
Section 16 reporting ended · disclosed 2018-06-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-06-04 transaction · row 1
1 source rowRow 1 · 2018-06-04 · Disposition to issuer · Disposed 1,318 · Balance 0 F1: Disposed of pursuant to that certain Amended and Restated Agreement and Plan of Merger ("Merger Agreement") dated as of July 9, 2017 by and among Great Plains Energy Incorporated ("Great Plains Energy"), Westar Energy, Inc., Evergy, Inc. ("Evergy") (formerly Monarch Energy Holding, Inc.), King Energy, Inc., and for certain limited purposes, GP Star, Inc. in exchange for shares of Evergy common stock at an exchange ratio of 0.5981 for each Great Plains Energy share on the effective date of the merger. On the effective date of the merger, the closing price of Great Plains Energy's common stock was $31.99 per share, and Evergy's common stock had not yet commenced trading on the New York Stock Exchange. |
| Director Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-04 · Disposition to issuer · Disposed 11,970 · Balance 0 F2: Director Deferred Share units are granted under the Long-Term Incentive Plan. Each unit represents the right to receive one share of Great Plains Energy Common Stock, plus stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person. F3: The Great Plains Energy Director Deferred Share units were exchanged for Evergy Director Deferred Share units pursuant to the Merger Agreement at an exchange ratio of 0.5981 for each Great Plains Energy share. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Amended and Restated Agreement and Plan of Merger ("Merger Agreement") dated as of July 9, 2017 by and among Great Plains Energy Incorporated ("Great Plains Energy"), Westar Energy, Inc., Evergy, Inc. ("Evergy") (formerly Monarch Energy Holding, Inc.), King Energy, Inc., and for certain limited purposes, GP Star, Inc. in exchange for shares of Evergy common stock at an exchange ratio of 0.5981 for each Great Plains Energy share on the effective date of the merger. On the effective date of the merger, the closing price of Great Plains Energy's common stock was $31.99 per share, and Evergy's common stock had not yet commenced trading on the New York Stock Exchange.
F2: Director Deferred Share units are granted under the Long-Term Incentive Plan. Each unit represents the right to receive one share of Great Plains Energy Common Stock, plus stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.
F3: The Great Plains Energy Director Deferred Share units were exchanged for Evergy Director Deferred Share units pursuant to the Merger Agreement at an exchange ratio of 0.5981 for each Great Plains Energy share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2021 Filed Dec 20, 2021 22:41 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 400 | $66.00 | $26,400.00 |
DisclosureSEC source: 0001666071-21-000247 · wf-form4_164004006562778.xml · nonDerivative · entry 5 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 53,112 F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F7 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $65.62 to $66.60, inclusive. F4 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 22:41 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 320 | $65.12 | $20,838.40 |
DisclosureSEC source: 0001666071-21-000247 · wf-form4_164004006562778.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 53,512 F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $64.56 to $65.55, inclusive. F4 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 22:41 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 640 | $63.88 | $40,883.20 |
DisclosureSEC source: 0001666071-21-000247 · wf-form4_164004006562778.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 53,832 F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $63.45 to $64.43, inclusive. F4 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 22:41 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 640 | $63.03 | $40,339.20 |
DisclosureSEC source: 0001666071-21-000247 · wf-form4_164004006562778.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 54,472 F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $62.45 to $63.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (5), (6), (7), (9), (10), (11) and (12) to this Form 4. F4 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 21:18 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,450 | $69.34 | $100,543.00 |
DisclosureSEC source: 0001666071-21-000238 · wf-form4_163943029639620.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,028 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on December 9, 2021. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $69.10 to $69.56, inclusive. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 21:18 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 10,645 | $68.64 | $730,672.80 |
DisclosureSEC source: 0001666071-21-000238 · wf-form4_163943029639620.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,478 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on December 9, 2021. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $68.10 to $69.07, inclusive. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 21:18 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 6,211 | $67.61 | $419,925.71 |
DisclosureSEC source: 0001666071-21-000238 · wf-form4_163943029639620.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,123 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on December 9, 2021. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $67.10 to $68.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (5) to this Form 4. Read SEC document |
| December 09, 2021 Filed Dec 13, 2021 21:18 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionPerformance Stock Unit · Derivative | 39,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-21-000238 · wf-form4_163943029639620.xml · derivative · entry 7 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,375 Underlying: Common Stock · 39,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: On December 9, 2021 the Compensation Committee of the Issuer's Board of Directors certified that a target minimum growth rate in adjusted contribution was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted contribution growth target ("adjusted contribution growth tranche"). Fifty percent (50%) of the shares subject to the adjusted contribution growth tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the adjusted contribution growth tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the adjusted contribution growth tranche of the awarded PSU will vest 12 months after the Certification, subject to continued service to the Issuer. F7 · derivative.expiration_date: On December 9, 2021 the Compensation Committee of the Issuer's Board of Directors certified that a target minimum growth rate in adjusted contribution was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted contribution growth target ("adjusted contribution growth tranche"). Fifty percent (50%) of the shares subject to the adjusted contribution growth tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the adjusted contribution growth tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the adjusted contribution growth tranche of the awarded PSU will vest 12 months after the Certification, subject to continued service to the Issuer. Read SEC document |
| December 09, 2021 Filed Dec 13, 2021 21:18 UTC | Cardlytics, Inc. CDLX · Entity 7603 | GrantPerformance Stock Unit · Derivative | 78,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-21-000238 · wf-form4_163943029639620.xml · derivative · entry 6 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 78,750 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: On December 9, 2021 the Compensation Committee of the Issuer's Board of Directors certified that a target minimum growth rate in adjusted contribution was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted contribution growth target ("adjusted contribution growth tranche"). Fifty percent (50%) of the shares subject to the adjusted contribution growth tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the adjusted contribution growth tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the adjusted contribution growth tranche of the awarded PSU will vest 12 months after the Certification, subject to continued service to the Issuer. F7 · derivative.expiration_date: On December 9, 2021 the Compensation Committee of the Issuer's Board of Directors certified that a target minimum growth rate in adjusted contribution was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted contribution growth target ("adjusted contribution growth tranche"). Fifty percent (50%) of the shares subject to the adjusted contribution growth tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the adjusted contribution growth tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the adjusted contribution growth tranche of the awarded PSU will vest 12 months after the Certification, subject to continued service to the Issuer. Read SEC document |
| December 09, 2021 Filed Dec 13, 2021 21:18 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 39,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001666071-21-000238 · wf-form4_163943029639620.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:08 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 100 | $65.20 | $6,520.00 |
DisclosureSEC source: 0001666071-21-000233 · wf-form4_163882849608205.xml · nonDerivative · entry 7 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,959 F5 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020, as amended June 15, 2021. F10 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $65.19 to $65.35, inclusive. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:08 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 300 | $64.06 | $19,218.00 |
DisclosureSEC source: 0001666071-21-000233 · wf-form4_163882849608205.xml · nonDerivative · entry 6 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,059 F5 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020, as amended June 15, 2021. F9 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $64.05 to $64.08, inclusive. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:08 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 684 | $62.99 | $43,085.16 |
DisclosureSEC source: 0001666071-21-000233 · wf-form4_163882849608205.xml · nonDerivative · entry 5 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,359 F5 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020, as amended June 15, 2021. F8 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $62.865 to $63.17, inclusive. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:08 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 3,816 | $62.23 | $237,469.68 |
DisclosureSEC source: 0001666071-21-000233 · wf-form4_163882849608205.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,043 F5 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020, as amended June 15, 2021. F7 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $61.85 to $62.84, inclusive. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:08 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,100 | $61.43 | $67,573.00 |
DisclosureSEC source: 0001666071-21-000233 · wf-form4_163882849608205.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,859 F5 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020, as amended June 15, 2021. F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $60.85 to $61.78, inclusive. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 22:08 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 300 | $65.23 | $19,569.00 |
DisclosureSEC source: 0001666071-21-000233 · wf-form4_163882849608205.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 55,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $64.83 to $65.43, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 22:08 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,700 | $64.34 | $109,378.00 |
DisclosureSEC source: 0001666071-21-000233 · wf-form4_163882849608205.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 55,412 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $63.82 to $64.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (6), (7), (8), (9), and (10) to this Form 4. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 200 | $83.11 | $16,622.00 |
DisclosureSEC source: 0001666071-21-000232 · wf-form4_163761976347022.xml · nonDerivative · entry 8 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,959 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020, as amended June 15, 2021. F9 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $82.76 to $83.45, inclusive. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 500 | $82.34 | $41,170.00 |
DisclosureSEC source: 0001666071-21-000232 · wf-form4_163761976347022.xml · nonDerivative · entry 7 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,159 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020, as amended June 15, 2021. F8 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $81.75 to $82.58, inclusive. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 310 | $80.97 | $25,100.70 |
DisclosureSEC source: 0001666071-21-000232 · wf-form4_163761976347022.xml · nonDerivative · entry 6 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,659 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020, as amended June 15, 2021. F7 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $80.69 to $81.38, inclusive. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,900 | $79.88 | $151,772.00 |
DisclosureSEC source: 0001666071-21-000232 · wf-form4_163761976347022.xml · nonDerivative · entry 5 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,969 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020, as amended June 15, 2021. F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $79.47 to $80.46, inclusive. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 617 | $78.48 | $48,422.16 |
DisclosureSEC source: 0001666071-21-000232 · wf-form4_163761976347022.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,869 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020, as amended June 15, 2021. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $77.95 to $78.87, inclusive. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 500 | $77.27 | $38,635.00 |
DisclosureSEC source: 0001666071-21-000232 · wf-form4_163761976347022.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,486 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020, as amended June 15, 2021. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $76.82 to $77.68, inclusive. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 871 | $76.03 | $66,222.13 |
DisclosureSEC source: 0001666071-21-000232 · wf-form4_163761976347022.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,986 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020, as amended June 15, 2021. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $75.74 to $76.69, inclusive. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,102 | $75.16 | $82,826.32 |
DisclosureSEC source: 0001666071-21-000232 · wf-form4_163761976347022.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,857 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020, as amended June 15, 2021. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $74.73 to $75.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8) and (9) to this Form 4. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 22:22 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 711 | $87.14 | $61,956.54 |
DisclosureSEC source: 0001666071-21-000230 · wf-form4_163718775090005.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 57,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $86.95 to $87.45, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 22:22 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 489 | $86.16 | $42,132.24 |
DisclosureSEC source: 0001666071-21-000230 · wf-form4_163718775090005.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 57,823 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $85.90 to $86.40, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 22:22 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 800 | $85.39 | $68,312.00 |
DisclosureSEC source: 0001666071-21-000230 · wf-form4_163718775090005.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 58,312 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $84.78 to $85.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), and (5) to this Form 4. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| November 05, 2021 Filed Nov 8, 2021 22:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,200 | $92.95 | $111,540.00 |
DisclosureSEC source: 0001666071-21-000224 · wf-form4_163641046601528.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,865 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on October 6, 2021. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $92.90 to $92.98, inclusive. Read SEC document |
| November 05, 2021 Filed Nov 8, 2021 22:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,500 | $92.31 | $138,465.00 |
DisclosureSEC source: 0001666071-21-000224 · wf-form4_163641046601528.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,065 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on October 6, 2021. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $91.88 to $92.85, inclusive. Read SEC document |
| November 05, 2021 Filed Nov 8, 2021 22:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 5,991 | $90.41 | $541,646.31 |
DisclosureSEC source: 0001666071-21-000224 · wf-form4_163641046601528.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,565 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on October 6, 2021. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $90.35 to $90.54, inclusive. Read SEC document |
| November 05, 2021 Filed Nov 8, 2021 22:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 9,493 | $90.13 | $855,604.09 |
DisclosureSEC source: 0001666071-21-000224 · wf-form4_163641046601528.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,556 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on October 6, 2021. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $89.35 to $90.345, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 20:44 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 40 | $81.74 | $3,269.60 |
DisclosureSEC source: 0001666071-21-000218 · wf-form4_163597222145698.xml · nonDerivative · entry 5 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 59,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 20:44 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 821 | $80.99 | $66,492.79 |
DisclosureSEC source: 0001666071-21-000218 · wf-form4_163597222145698.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 59,152 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $80.62 to $81.59, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 20:44 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 280 | $80.15 | $22,442.00 |
DisclosureSEC source: 0001666071-21-000218 · wf-form4_163597222145698.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 59,973 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $79.58 to $80.57, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 20:44 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 399 | $79.17 | $31,588.83 |
DisclosureSEC source: 0001666071-21-000218 · wf-form4_163597222145698.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 60,253 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $78.57 to $79.55, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 20:44 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 460 | $78.07 | $35,912.20 |
DisclosureSEC source: 0001666071-21-000218 · wf-form4_163597222145698.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 60,652 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $77.53 to $78.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5) and (6) to this Form 4. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| October 18, 2021 Filed Oct 19, 2021 20:47 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 302 | $84.07 | $25,389.14 |
DisclosureSEC source: 0001666071-21-000204 · wf-form4_163467643163096.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 61,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $83.99 to $84.11, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| October 18, 2021 Filed Oct 19, 2021 20:47 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,698 | $83.57 | $141,901.86 |
DisclosureSEC source: 0001666071-21-000204 · wf-form4_163467643163096.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 61,414 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $82.98 to $83.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| October 06, 2021 Filed Oct 6, 2021 22:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionPerformance Stock Unit · Derivative | 39,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-21-000200 · wf-form4_163355849461568.xml · derivative · entry 7 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,375 Underlying: Common Stock · 39,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. F9 · derivative.exercise_date: On October 6, 2021 the Compensation Committee of the Issuer's Board of Directors certified that a target minimum number of advertisers with a specified billings threshold over a trailing 12-month period was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the advertiser count target ("advertiser tranche"). Fifty percent (50%) of the shares subject to the advertiser tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the advertiser tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the advertiser tranche of the awarded PSU will vest 12 months after the Certification, subject to continued service to the Issuer. F9 · derivative.expiration_date: On October 6, 2021 the Compensation Committee of the Issuer's Board of Directors certified that a target minimum number of advertisers with a specified billings threshold over a trailing 12-month period was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the advertiser count target ("advertiser tranche"). Fifty percent (50%) of the shares subject to the advertiser tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the advertiser tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the advertiser tranche of the awarded PSU will vest 12 months after the Certification, subject to continued service to the Issuer. Read SEC document |
| October 06, 2021 Filed Oct 6, 2021 22:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | GrantPerformance Stock Unit · Derivative | 78,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-21-000200 · wf-form4_163355849461568.xml · derivative · entry 6 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 78,750 shares Expires not disclosed F8 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. F9 · derivative.exercise_date: On October 6, 2021 the Compensation Committee of the Issuer's Board of Directors certified that a target minimum number of advertisers with a specified billings threshold over a trailing 12-month period was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the advertiser count target ("advertiser tranche"). Fifty percent (50%) of the shares subject to the advertiser tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the advertiser tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the advertiser tranche of the awarded PSU will vest 12 months after the Certification, subject to continued service to the Issuer. F9 · derivative.expiration_date: On October 6, 2021 the Compensation Committee of the Issuer's Board of Directors certified that a target minimum number of advertisers with a specified billings threshold over a trailing 12-month period was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the advertiser count target ("advertiser tranche"). Fifty percent (50%) of the shares subject to the advertiser tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the advertiser tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the advertiser tranche of the awarded PSU will vest 12 months after the Certification, subject to continued service to the Issuer. Read SEC document |
| October 06, 2021 Filed Oct 6, 2021 22:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 39,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001666071-21-000200 · wf-form4_163355849461568.xml · nonDerivative · entry 5 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: Represents the underlying vested shares of common stock of the Issuer which have not been delivered. F8 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 22:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 557 | $82.04 | $45,696.28 |
DisclosureSEC source: 0001666071-21-000200 · wf-form4_163355849461568.xml · nonDerivative · entry 4 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 63,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $81.65 to $82.53, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 22:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 138 | $81.12 | $11,194.56 |
DisclosureSEC source: 0001666071-21-000200 · wf-form4_163355849461568.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 63,669 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $80.61 to $81.52, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 22:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 501 | $80.00 | $40,080.00 |
DisclosureSEC source: 0001666071-21-000200 · wf-form4_163355849461568.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 63,807 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $79.58 to $80.52, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 22:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 804 | $78.98 | $63,499.92 |
DisclosureSEC source: 0001666071-21-000200 · wf-form4_163355849461568.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 64,308 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $78.58 to $79.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5) and (6) to this Form 4. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 21:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 3,000 | $90.00 | $270,000.00 |
DisclosureSEC source: 0001666071-21-000183 · wf-form4_163225937398606.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,674 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2020, as amended June 15, 2021. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 12:50 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 100 | $92.83 | $9,283.00 |
DisclosureSEC source: 0001666071-21-000181 · wf-form4_163214221998961.xml · nonDerivative · entry 3 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 65,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 12:50 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 809 | $92.09 | $74,500.81 |
DisclosureSEC source: 0001666071-21-000181 · wf-form4_163214221998961.xml · nonDerivative · entry 2 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 65,212 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $91.70 to $92.65, inclusive. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 12:50 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,091 | $90.98 | $99,259.18 |
DisclosureSEC source: 0001666071-21-000181 · wf-form4_163214221998961.xml · nonDerivative · entry 1 Grimes Scott D. · CIK 0001617486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 66,021 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $90.59 to $91.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. F3 · ownership.nature: The reportable securities are held by the GRAT. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.